Midkine expression in oral squamous cell carcinoma and leukoplakia

Department of Microbiology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil.
Journal of Oral Pathology and Medicine (Impact Factor: 1.93). 05/2011; 41(1):21-6. DOI: 10.1111/j.1600-0714.2011.01049.x
Source: PubMed


Midkine (MK), a 13-kDa heparin-binding growth factor, is overexpressed in various human cancers. However, its role in the development and progression of oral cavity squamous cell carcinoma (OCSCC) is still unclear. Thus, the aim of this study was to evaluate the expression of MK in samples of OCSCC, leukoplakia, and healthy oral mucosa (control).
Surgically excised specimens from patients with primary OCSCC (n = 28) were immunostained for MK, Ki-67, PCNA, p53, bcl-2, Bax, and CD31. Besides this, MK expression was also investigated in leukoplakia and normal oral mucosa. The relationship of MK(+) cells with clinical parameters (tumor location, tumor size, lymph node metastasis, and survival) and microscopic parameters (WHO histological grading, intensity of inflammation, proliferation index, apoptosis, and angiogenesis) was also evaluated.
The results showed that MK expression was increased in OCSCC in relation to leukoplakia and normal mucosa. Furthermore, MK expression was increased in late-stage tumors (T3/T4) compared with early-stage lesions (T1/T2). MK-positive lesions also showed increased expression of the anti-apoptotic protein bcl-2.
OCSCC, particularly late-stage tumors, exhibits increased MK expression, which may be involved in tumor progression via upregulation of anti-apoptotic genes, as shown by the augmented bcl-2 positivity in MK-positive tumors.

Download full-text


Available from: Tarcilia A Silva, Mar 19, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ribosomal protein S6 (RPS6), a downstream effector of the mammalian target of rapamycin pathway (mTOR), is activated in many cancers including oral squamous cell carcinoma (OSCC). However, the role of RPS6 in the progression of potentially malignant disorders (or premalignant lesions) to OSCC is unknown. The purpose of this study was to examine the expression of RPS6 in epithelial dysplasia and OSCC to determine the association of RPS6 in tumor progression. In our study, an immunohistochemical analysis of RPS6 was performed on tissue microarrays containing 30 control samples, 15 epithelial dysplasia cases, and 53 OSCC cases. Correlations between the clinicopathologic features of OSCC and RPS6 expression were analyzed using the Chi-square test. We found RPS6 phosphorylation (p-RPS6) in 15/30 (50 %) control normal oral mucosa samples, 15/15 (100 %) epithelial dysplasia cases, and 47/53 (88.68 %) OSCC cases. The frequency of p-RPS6 in epithelial dysplasia or OSCC showed a statistically significant difference compared to control (P < 0.001). However, there were no significant correlations between p-RPS6 and the clinicopathologic features of OSCC. Our findings suggest that RPS6 activation is associated with the early events of tumor progression, suggesting p-RPS6 as a potential marker for early detection of oral cancer.
    Pathology & Oncology Research 09/2012; 19(2). DOI:10.1007/s12253-012-9568-y · 1.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Midkine is a heparin-binding di-domain growth factor, implicated in many biological processes as diverse as angiogenesis, neurogenesis and tumorigenesis. Elevated midkine levels reflect poor prognosis for many carcinomas, yet the molecular and cellular mechanisms orchestrating its activity remain unclear. Presently, the individual structures of isolated half domains of human midkine are known and its functionally active C-half domain remains a popular therapeutic target. Here, we determined the structure of full length zebrafish midkine and show that it interacts with fondaparinux (a synthetic, highly sulfated pentasaccharide) and natural heparin through a previously uncharacterized but highly conserved hinge region. Mutating six consecutive residues in the conserved hinge to glycine residues strongly abates heparin-binding and midkine embryogenic activity. In contrast to previous in vitro studies, we find that the isolated C-half domain is not active in vivo in embryos. Instead, we demonstrate that the N-half domain is needed to enhance heparin-binding and mediate midkine embryogenic activity surprisingly in both heparin-dependent and -independent manners. Our findings provide new insights into the structural features of full length midkine relevant for embryogenesis, and unravel additional therapeutic routes targeting the N-half domain and conserved hinge.
    Biochemical Journal 02/2013; 451(3). DOI:10.1042/BJ20121622 · 4.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To date, the term oral leukoplakia (OL) should be used to recognize ‘predominantly white plaques of questionable risk, having excluded (other) known diseases or disorders that carry no increased risk of cancer’. In this review, we addressed four controversial topics regarding oral leukoplakias (OLs): (i) Do tobacco and alcohol cause OLs?, (ii) What percentage of OLs transform into oral squamous cell carcinoma (OSCC)?, (iii) Can we distinguish between premalignant and innocent OLs?, and (iv) Is proliferative verrucous leukoplakia (PVL) a specific entity or just a form of multifocal leukoplakia? Results of extensive literature search suggest that (i) no definitive evidence for direct causal relationship between smoked tobacco and alcohol as causative factors of OLs, (ii and iii) the vast majority of OLs follow a benign course and do not progress into a cancer, and no widely accepted and/or validated clinical and/or biological factors can predict malignant transformation, and (iv) the distinction between multifocal/multiple leukoplakias and PVL in their early presentation is impossible; the temporal clinical progression and the high rate of recurrences and development of cancer of PVL are the most reliable features for diagnosis.
    Oral Diseases 10/2013; 19(7). DOI:10.1111/odi.12065 · 2.43 Impact Factor
Show more